ESR1 and breast cancer: Together, these results indicate that AEs can induce ERα SUMOylation in ER+ breast cancer cells and in transfected ER-negative cells with a range of efficacies correlating with the length of the AE side chain and/or the bulk of terminal hydrophobic groups, cell-specific effects being observed for some AEs at the lower end of the efficacy spectrum.